Navigation Links
Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
Date:1/15/2014

OXFORD, England and SAN JOSE, California, January 15, 2014 /PRNewswire/ --

Oxford BioTherapeutics, an international biotechnology company developing antibody-drug conjugates for cancer, today announced the appointment of Thomas C Reynolds MD, PhD to its Board of Directors. Dr Reynolds has over 20 years' development experience gained in the biotechnology industry, most recently as Chief Medical Officer at Seattle Genetics.

"I am delighted to welcome Tom at this transformative time for Oxford BioTherapeutics, as the company completes its transition into a fully-fledged oncology product development business," said Bryan Morton, Chairman of Oxford BioTherapeutics. "Dr Reynolds' experience in the oncology field will prove invaluable as we progress our pipeline into the clinic, and in particular his expertise in bringing antibody-drug conjugates to market having led the development and approval of ADCETRIS at Seattle Genetics."

Commenting on his appointment, Thomas C Reynolds MD, PhD, said, "I am highly impressed with Oxford BioTherapeutics' cancer targeting technology, which has continued to mature since my tenure at Seattle Genetics. I am delighted to be able to contribute to the development of the company's exciting antibody-based oncology products."

About Thomas C Reynolds MD, PhD

Dr Reynolds has held a number of senior development roles during his career of over 20 years in the biotechnology industry. Most recently he was Chief Medical Officer at Seattle Genetics, where he had direct oversight of the development and approval of the company's antibody-drug conjugate, ADCETRIS. Prior to this, he was Vice President for Medical Affairs at Zymogenetics, having held the role of Senior Medical Director. Previously, he held a number of senior roles at Targeted Genetics Corporation, culminating in the position of Vice President, Clinical A
'/>"/>

SOURCE Oxford BioTherapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oxford University Press to publish BioScience journal starting in 2014
2. Oxford BioMedica Announces Update from ARVO 2013
3. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
4. Oxford Performance Materials and Biomet Microfixation Join Forces
5. Oxford University Hospitals NHS Trust and the Bodleian Libraries Select ClinicalKey
6. Oxford Finance Completes $271.4 Million Securitization Transaction
7. Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Roger Jeffs , ... provide an overview and update on the company,s business at ... in Boston, Massachusetts . The ... 3:30 PM Eastern Time, and can be accessed via a ...
(Date:4/30/2015)... 30, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, announced ... quarter of 2015 on May 7, 2015 after the ... will also host a conference call at 4:30 p.m. ... first quarter financial results. During the conference call, material ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Cytokinetics, Incorporated (Nasdaq: ... quarter of 2015 were $4.4 million, compared to $8.0 million ... for the first quarter was $8.9 million, or $0.23 per ... loss for the same period in 2014, of $8.7 million, ... March 31, 2015, cash, cash equivalents and investments totaled $117.5 ...
(Date:4/30/2015)... Nitto Avecia, a leading biotechnology manufacturer ... and production capability to serve biotechnology pharmaceutical clients. ... fulfillment continues to drive Nitto Avecia to enhance ... , In Fall 2014, Nitto Avecia ... at its Milford, MA facility, which is recognized ...
Breaking Biology Technology:Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2
... Oct. 5 ISTO Technologies, Inc. (ISTO), an  orthobiologics ... today the completion of patient enrollment in the Phase ... formulation of juvenile chondrocytes designed for the treatment of ... at two clinical sites. All patients enrolled in the ...
... the many pressing concerns of the day, fear of plague ... for those whose responsibility it is to combat bioterrorism, plague ... include scientists like medical researcher Steve Smiley, whose lab at ... will protect the public against weaponized forms of plague. The ...
... AMGN ) today announced that results from ... evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX or ... colorectal cancer (mCRC), respectively, were published online in the ... "Both studies demonstrated that Vectibix administered with chemotherapy significantly ...
Cached Biology Technology:ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3Plague researchers race to beat bioterrorists 2Plague researchers race to beat bioterrorists 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11
(Date:4/27/2015)... OXFORD, Conn. , Apr. 27, 2015 ... "Company"), a biometric authentication company focused on the growing ... will commence shipping to pre-order customers the first week ... pre-orders through the month of May. ... is a significant milestone for the company as Wocket® ...
(Date:4/17/2015)... April 17, 2015 ... and technological advancement to drive biometric systems market ... 2020   According to a recently ... Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... register growth at CAGR of over 22% through ...
(Date:4/10/2015)... April 10, 2015 Research and ... the "Security Competitive Profiles - NEC" report ... NEC will continue to supply a range ... market, with a company focus on the development of ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2
... While many bacteria exist as aggressive pathogens, causing diseases ... toxic shock syndrome, others play a less malevolent role ... a new study, Cheryl Nickerson and her group at ... including Tom Van de Wiele and lead author Rosemarie ...
... , adds to our understanding of the role of stem and ... and treatment of cancer. , While stem cells are known to ... difficult to isolate. The new findings show that an antibody developed ... , Professor Pera, program leader for Stem Cells Australia and Chair ...
... Manchester have uncovered how the internal mechanisms in nerve ... avenues in the investigation of neurodegenerative diseases by analysing ... Prokop and his team at the Faculty of Life ... thin cable-like extensions of nerve cells that wire the ...
Cached Biology News:Beneficial bacteria may help ward off infection 2Beneficial bacteria may help ward off infection 3Beneficial bacteria may help ward off infection 4Beneficial bacteria may help ward off infection 5Stem cell research aids understanding of cancer 2Cell research opens new avenues in combating neurodegenerative diseases 2Cell research opens new avenues in combating neurodegenerative diseases 3
Agar, 500 g. Noble Agar.Moisture: < 10%, ash: < 1.6%, EEO (-mr): < 0.450 (pH 8.4). Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
MW5...
From micro to giga sizes, from single prep to high-throughput, Invitrogen's range of plasmid purification kits offers superior performance to match the demands of your downstream application....
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Biology Products: